2025 Q4 -tulosraportti
Vain PDF
114 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenJust out of curiosity, how many shares are people holding?
·3 t sittenReading a bit in the registration form for the general meeting 25/08-2026. It states there: "According to the Public Limited Liability Companies Act section 10-14, the board is authorized to increase the company's share capital by up to NOK 32.955.349,20." Does this mean they will carry out a share issue yet again or are they just asking for authorization to be able to do this?
Questions and answers from Erik during the warrant period. The answer is from June 5, possibly something the board is speculating on here. I don't think there will be a new share issue, but if the opportunities arise, they have the possibility to raise quick capital for, for example, complementary vector or delivery technology that makes Circio more independent. Question I have thoroughly familiarized myself with the warrant setup, including the role of the guarantors and the minimum amount of 150 million. My main focus is what happens if participation from existing shareholders is high, so that the company raises significantly more than the minimum (potentially up to the 300 mill. target). As a private investor, I am concerned with good capital discipline and that any dilution creates corresponding value. If the warrant program receives high participation, how will you prioritize the excess capital to accelerate the pipeline (especially the circVec platform and the heart program) and maximize shareholder value? I have great faith in the circVec platform and their technology, but I would like to hear management's thoughts on the management of any excess liquidity before I commit further capital. ------------------------------ Thank you for your engagement in Circio! We can achieve the most important milestones by raising a minimum of 150 mill (secured) and preferably 300 mill (likely). Here we have communicated a clear use-of-proceeds that secures runway until 2030, achieves valuable R&D milestones along the way, and makes it possible to build a biotech company of international caliber. If we raise significantly more than NOK 300 mill, we will conduct a strategic analysis of the situation together with the board so that this capital is used smartly. In such a case, it may be relevant to consider two IND/clinical tracks in parallel (e.g., adding eye or in vivo CAR). It may also be relevant to look at the purchase/acquisition of complementary vector or delivery technology that makes Circio more independent - this can be particularly relevant within the LNP-DNA / cell therapy program where we are dependent on combining with external technology that works in synergy with circVec. We have been through a period with very limited resources, so I can assure you that the organization is focused on - and accustomed to - being cost-effective. This will not change. That said, we will now be able to do more work in parallel and take greater R&D risk where it makes sense to accelerate timelines and broaden the scope of possibilities inherent in the platform.
·7 t sittenThis is how the pipeline looks now on the homepage. It's possible it has been commented on before, but in that case, I haven't caught it, apart from what was discussed about the second draft. The old Targo studies have also been removed. https://www.circio.com/en/our-pipeline/
·7 t sittenCHEERS. 🥂🧬 The bell rings, screens turn off, and everyone goes home. But here's the thing: the case doesn't sleep on the weekend. 👀 News for this stock doesn't come neatly at nine o'clock on a Tuesday. It comes anytime — late on a Friday, early on a Sunday, without warning. We've seen it before. And that's the whole point: you can't position yourself for it when it happens. Only before. ♟️ So while others close the app and forget what they own — we know exactly what we're sitting on. Full cash. Data maturing. An autumn that is loaded to the brim. 🧱 Happy weekend, folks. Enjoy the calm while it lasts. 😎 We know what we own. ♟️🧱🍷
The best thing about the weekend is the church bells ringing on Sunday. Then it's finally almost Monday😇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
114 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenJust out of curiosity, how many shares are people holding?
- ·3 t sittenReading a bit in the registration form for the general meeting 25/08-2026. It states there: "According to the Public Limited Liability Companies Act section 10-14, the board is authorized to increase the company's share capital by up to NOK 32.955.349,20." Does this mean they will carry out a share issue yet again or are they just asking for authorization to be able to do this?Questions and answers from Erik during the warrant period. The answer is from June 5, possibly something the board is speculating on here. I don't think there will be a new share issue, but if the opportunities arise, they have the possibility to raise quick capital for, for example, complementary vector or delivery technology that makes Circio more independent. Question I have thoroughly familiarized myself with the warrant setup, including the role of the guarantors and the minimum amount of 150 million. My main focus is what happens if participation from existing shareholders is high, so that the company raises significantly more than the minimum (potentially up to the 300 mill. target). As a private investor, I am concerned with good capital discipline and that any dilution creates corresponding value. If the warrant program receives high participation, how will you prioritize the excess capital to accelerate the pipeline (especially the circVec platform and the heart program) and maximize shareholder value? I have great faith in the circVec platform and their technology, but I would like to hear management's thoughts on the management of any excess liquidity before I commit further capital. ------------------------------ Thank you for your engagement in Circio! We can achieve the most important milestones by raising a minimum of 150 mill (secured) and preferably 300 mill (likely). Here we have communicated a clear use-of-proceeds that secures runway until 2030, achieves valuable R&D milestones along the way, and makes it possible to build a biotech company of international caliber. If we raise significantly more than NOK 300 mill, we will conduct a strategic analysis of the situation together with the board so that this capital is used smartly. In such a case, it may be relevant to consider two IND/clinical tracks in parallel (e.g., adding eye or in vivo CAR). It may also be relevant to look at the purchase/acquisition of complementary vector or delivery technology that makes Circio more independent - this can be particularly relevant within the LNP-DNA / cell therapy program where we are dependent on combining with external technology that works in synergy with circVec. We have been through a period with very limited resources, so I can assure you that the organization is focused on - and accustomed to - being cost-effective. This will not change. That said, we will now be able to do more work in parallel and take greater R&D risk where it makes sense to accelerate timelines and broaden the scope of possibilities inherent in the platform.
- ·7 t sittenThis is how the pipeline looks now on the homepage. It's possible it has been commented on before, but in that case, I haven't caught it, apart from what was discussed about the second draft. The old Targo studies have also been removed. https://www.circio.com/en/our-pipeline/
- ·7 t sittenCHEERS. 🥂🧬 The bell rings, screens turn off, and everyone goes home. But here's the thing: the case doesn't sleep on the weekend. 👀 News for this stock doesn't come neatly at nine o'clock on a Tuesday. It comes anytime — late on a Friday, early on a Sunday, without warning. We've seen it before. And that's the whole point: you can't position yourself for it when it happens. Only before. ♟️ So while others close the app and forget what they own — we know exactly what we're sitting on. Full cash. Data maturing. An autumn that is loaded to the brim. 🧱 Happy weekend, folks. Enjoy the calm while it lasts. 😎 We know what we own. ♟️🧱🍷The best thing about the weekend is the church bells ringing on Sunday. Then it's finally almost Monday😇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
114 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenJust out of curiosity, how many shares are people holding?
- ·3 t sittenReading a bit in the registration form for the general meeting 25/08-2026. It states there: "According to the Public Limited Liability Companies Act section 10-14, the board is authorized to increase the company's share capital by up to NOK 32.955.349,20." Does this mean they will carry out a share issue yet again or are they just asking for authorization to be able to do this?Questions and answers from Erik during the warrant period. The answer is from June 5, possibly something the board is speculating on here. I don't think there will be a new share issue, but if the opportunities arise, they have the possibility to raise quick capital for, for example, complementary vector or delivery technology that makes Circio more independent. Question I have thoroughly familiarized myself with the warrant setup, including the role of the guarantors and the minimum amount of 150 million. My main focus is what happens if participation from existing shareholders is high, so that the company raises significantly more than the minimum (potentially up to the 300 mill. target). As a private investor, I am concerned with good capital discipline and that any dilution creates corresponding value. If the warrant program receives high participation, how will you prioritize the excess capital to accelerate the pipeline (especially the circVec platform and the heart program) and maximize shareholder value? I have great faith in the circVec platform and their technology, but I would like to hear management's thoughts on the management of any excess liquidity before I commit further capital. ------------------------------ Thank you for your engagement in Circio! We can achieve the most important milestones by raising a minimum of 150 mill (secured) and preferably 300 mill (likely). Here we have communicated a clear use-of-proceeds that secures runway until 2030, achieves valuable R&D milestones along the way, and makes it possible to build a biotech company of international caliber. If we raise significantly more than NOK 300 mill, we will conduct a strategic analysis of the situation together with the board so that this capital is used smartly. In such a case, it may be relevant to consider two IND/clinical tracks in parallel (e.g., adding eye or in vivo CAR). It may also be relevant to look at the purchase/acquisition of complementary vector or delivery technology that makes Circio more independent - this can be particularly relevant within the LNP-DNA / cell therapy program where we are dependent on combining with external technology that works in synergy with circVec. We have been through a period with very limited resources, so I can assure you that the organization is focused on - and accustomed to - being cost-effective. This will not change. That said, we will now be able to do more work in parallel and take greater R&D risk where it makes sense to accelerate timelines and broaden the scope of possibilities inherent in the platform.
- ·7 t sittenThis is how the pipeline looks now on the homepage. It's possible it has been commented on before, but in that case, I haven't caught it, apart from what was discussed about the second draft. The old Targo studies have also been removed. https://www.circio.com/en/our-pipeline/
- ·7 t sittenCHEERS. 🥂🧬 The bell rings, screens turn off, and everyone goes home. But here's the thing: the case doesn't sleep on the weekend. 👀 News for this stock doesn't come neatly at nine o'clock on a Tuesday. It comes anytime — late on a Friday, early on a Sunday, without warning. We've seen it before. And that's the whole point: you can't position yourself for it when it happens. Only before. ♟️ So while others close the app and forget what they own — we know exactly what we're sitting on. Full cash. Data maturing. An autumn that is loaded to the brim. 🧱 Happy weekend, folks. Enjoy the calm while it lasts. 😎 We know what we own. ♟️🧱🍷The best thing about the weekend is the church bells ringing on Sunday. Then it's finally almost Monday😇
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt